Location History:
- Chicago, IL (US) (1993 - 1999)
- Cohoes, NY (US) (2007)
- Wilmette, IL (US) (1995 - 2009)
Company Filing History:
31 out of 2,345 
1 out of 3 
1 out of 5 Years Active: 1993-2009
Title: Innovations in Multidrug Resistance: The Contributions of Igor B. Roninson
Introduction
Igor B. Roninson is a prominent inventor and researcher based in Wilmette, IL, whose work has significantly impacted the field of cancer treatment, particularly in understanding multidrug resistance. With a total of 36 patents to his name, he continues to push the boundaries of medical science with his innovative approaches.
Latest Patents
Among his latest patents are pioneering inventions related to monoclonal antibodies targeting the human MDR1 multidrug resistance gene product. One notable patent outlines the creation of a hybridoma known as 'UIC2 hybridoma', producing monoclonal antibodies termed 'UIC2 mAb'. These antibodies specifically target an extracellular domain of P-glycoprotein, which is associated with multidrug resistance in primate cells. This invention facilitates the detection and isolation of multidrug-resistant cells and aims to reverse resistance in human tumors. Another significant patent involves mutant P-glycoprotein polypeptides that enhance resistance to chemotherapeutic drugs, along with antibodies that bind specifically to these mutant forms. This also includes methodologies for diagnosing and treating conditions linked to P-glycoprotein-mediated multidrug resistance.
Career Highlights
Throughout his career, Igor has contributed substantially to academic and research institutions, most notably at the University of Illinois. His work has not only enriched scientific literature but has led to practical applications in combating drug resistance, a major hurdle in effective cancer treatment.
Collaborations
Igor Roninson has collaborated with notable colleagues including Andrei V. Gudkov and Tatyana Holzmayer. These partnerships have fostered advancements in research and innovation, enhancing the understanding and treatment of multidrug resistance.
Conclusion
Igor B. Roninson's contributions to innovations in the field of multidrug resistance exemplify the critical role of inventors in advancing medical research. His patents not only reflect his dedication to science but also highlight the potential for breakthroughs in cancer treatment that may arise from his innovative approaches. As the fight against cancer continues, the impact of Roninson’s work will undoubtedly shape future therapeutic strategies.